KHYG-1Homo sapiens (Human)Cancer cell line

Also known as: KHYG, KHYG1

🤖 AI SummaryBased on 7 publications

Quick Overview

KHYG-1 is a human natural killer (NK) cell line established from aggressive NK cell leukemia with a p53 point mutation.

Detailed Summary

KHYG-1 is a human natural killer (NK) cell line derived from a patient with aggressive NK cell leukemia. It is characterized by the presence of a p53 point mutation, which may contribute to its malignant properties. The cell line exhibits large granular lymphocyte (LGL) morphology with a high cytoplasm-to-nucleus ratio and abundant azurophilic granules. KHYG-1 is IL-2-dependent and has been used in studies to investigate the role of STAT3 and STAT5B mutations in NK-cell malignancies. It is also known for its high expression of NK cell markers such as CD56 and CD16, and its ability to produce cytokines and exhibit cytotoxic activity against target cells. The cell line has been utilized in research to understand the molecular mechanisms underlying NK cell leukemia and to develop targeted therapies.

Research Applications

Investigation of p53 mutations in NK cell malignanciesStudy of STAT3 and STAT5B mutations in NK-cell lymphomasAnalysis of IL-2-dependent growth and cytotoxic activityMolecular profiling of NK cell leukemiaDevelopment of targeted therapies for NK cell malignancies

Key Characteristics

IL-2-dependent growthLarge granular lymphocyte morphologyExpression of NK cell markers (CD56, CD16)Presence of p53 point mutationHigh cytotoxic activity against target cells

Generated on 6/19/2025

Basic Information

Database ID	CVCL_2976
Species	Homo sapiens (Human)
Tissue Source	Peripheral blood[UBERON:UBERON_0000178]

Donor Information

Age	45
Age Category	Adult
Sex	Female

Disease Information

Disease	Natural killer cell lymphoblastic leukemia/lymphoma
Lineage	Lymphoid
Subtype	Natural Killer (NK) Cell Lymphoblastic Leukemia/Lymphoma (NKCLL)
OncoTree Code	NKCLL

DepMap Information

Source Type	Academic lab
Source ID	ACH-001100_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	TP53	p.Arg248Trp (c.742C>T)	Homozygous	Somatic mutation acquired during proliferation	from parent cell line VCaP
MutationSimple	KRAS	p.Gly12Ala (c.35G>C)	Unspecified	-	PubMed=21173094

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

CSF1PO

D13S317

9,13

D16S539

D18S51

13,18

D19S433

13,14

D21S11

30,32.2

D2S1338

17,19

D3S1358

15,16

D5S818

9,11

D7S820

10,11

D8S1179

FGA

21,24

Penta D

11,13

Penta E

TH01

TPOX

9,11

vWA

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

The LL-100 panel: 100 cell lines for blood cancer studies.";

MacLeod R.A.F., Nagel S., Steube K.G., Uphoff C.C., Drexler H.G.

Sci. Rep. 9:8218-8218(2019).

DOI PubMed PMC

Activating mutations of STAT5B and STAT3 in lymphomas derived from gammadelta-T or NK cells.

de Leval L., McKeithan T.W., Chan W.-C.

Nat. Commun. 6:6025.1-6025.12(2015).

DOI PubMed PMC

Natural killer cell lymphoma shares strikingly similar molecular features with a group of non-hepatosplenic gammadelta T-cell lymphoma and is highly sensitive to a novel aurora kinase A inhibitor in vitro.

Sng I., Liu X., Loughran T.P. Jr., Armitage J.O., Chan W.-C.

Leukemia 25:348-358(2011).

DOI PubMed

Genomic analyses reveal global functional alterations that promote tumor growth and novel tumor suppressor genes in natural killer-cell malignancies.

Tsui I.F.L., Ali H.H., Shimizu N., Au W.Y., Lam W.L., Chan W.-C.

Leukemia 23:1139-1151(2009).

DOI PubMed

Alterations in ATR in nasal NK/T-cell lymphoma and chronic active Epstein-Barr virus infection.

Liu A., Takakuwa T., Luo W.-J., Fujita S., Aozasa K.

Cancer Sci. 97:605-610(2006).

DOI PubMed PMC

A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation.

Konaka Y., Takatsuki K.

Leukemia 14:922-930(2000).

DOI PubMed

Malignant hematopoietic cell lines: in vitro models for the study of natural killer cell leukemia-lymphoma.

Drexler H.G., Matsuo Y.

Leukemia 14:777-782(2000).

DOI PubMed

The leukemia-lymphoma cell line factsbook.";

Drexler H.G.

(In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).

DOI

Web Resources

en.wikipedia.org